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Functional social support has a stronger association with medical treatment adherence
than structural social support in several populations and disease conditions. Using a con-
temporary U.S. population of adults treated with medications for coronary heart disease
(CHD) risk factors, the association between social support and medication adherence was
examined.
Methods
We included 17,113 black and white men and women with CHD or CHD risk factors aged
45 years recruited 2003–2007 from the REasons for Geographic and Racial Differences in
Stroke (REGARDS) study. Participants reported their perceived social support (structural
social support: being partnered, number of close friends, number of close relatives, and num-
ber of other adults in household; functional social support: having a caregiver in case of sick-
ness or disability; combination of structural and functional social support: number of close
friends or relatives seen at least monthly). Medication adherence was assessed using a 4-
item scale. Multi-variable adjusted Poisson regression models were used to calculate preva-
lence ratios (PR) for the association between social support and medication adherence.
Results
Prevalence of medication adherence was 68.9%. Participants who saw >10 close friends or
relatives at least monthly had higher prevalence of medication adherence (PR = 1.06; 95%
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CI: 1.00, 1.11) than those who saw3 per month. Having a caregiver in case of sickness or
disability, being partnered, number of close friends, number of close relatives, and number
of other adults in household were not associated with medication adherence after adjusting
for covariates.
Conclusions
Seeing multiple friends and relatives was associated with better medication adherence
among individuals with CHD risk factors. Increasing social support with combined structural
and functional components may help support medication adherence.
Introduction
Medications can reduce the risk of coronary heart disease (CHD) events and mortality among
people with known CHD and/or CHD risk factors such as diabetes, hypertension, and dyslipi-
demia [1–3]. However, a meta-analysis indicated that only 50 to 66% of patients were adherent
to cardiovascular medications [4]. Some evidence suggests that social support promotes medi-
cation adherence in chronic disease management [5–10]. Social networks provide social sup-
port via a series of relationships and interconnectedness through which members influence
each other’s behaviors by their daily interactions and feedback mechanisms [11]. These net-
works may increase treatment adherence through support received from relatives and friends
as well as assistance provided for self-care activities [9]. However, social network members
may discourage others from using certain medications, thereby reducing adherence [11].
Social support has been conceptualized as consisting of functional support, structural sup-
port, and informational support [6, 12, 13]. Functional social support includes practical help
provided by an individual’s social network (e.g., providing transportation to doctor’s visits,
saying encouraging words, providing care during illness) [6, 12, 13]. Structural social support
refers to the number and types of connection within an individual’s social network (e.g., social
network size, living arrangement, marital status) [6, 12, 13]. Informational support is the
knowledge provided to an individual through their social network (e.g., providing reading
material about a recent diagnosis) [6, 12, 13]. In two prior meta-analyses, functional social sup-
port was more strongly associated with treatment adherence than structural social support [6,
14]. It is unclear whether functional and structural social support affect medication adherence
specifically among those with CHD risk factors other than diabetes.
In addition, how social networks operate and how social support is received may vary by
race and gender. Prior studies have found that black households may have more members
compared to white households to mitigate costs due to low income [12, 15, 16], blacks depend
more on informal social networks for chronic disease management than whites [12, 17–19],
and blacks generally have lower medication adherence compared to whites [20–24]. Moreover,
differences by gender have been reported with men being more likely to report more support
from their partners while women were more likely to receive support from their friends, rela-
tives, and peers [25–27].
The aim of the present study is to investigate the associations between perceived functional
and structural social support and medication adherence in a large population of black and
white men and women treated with medications for CHD risk factors. Additionally, we exam-
ined whether the associations between perceived social support and medication adherence var-
ied by race and, separately, by gender.
Social support and medication adherence
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The REasons for Geographic and Racial Differences in Stroke (REGARDS) study is a cohort of
30,239 English-speaking, community-dwelling, black and white adults age 45 and older who
lived in the 48 contiguous U.S. at enrollment between 2003–2007 [28]. The REGARDS study
was designed to investigate racial and regional variations in stroke mortality, and oversampled
black individuals and people living in the U.S. stroke buckle (coastal regions of North Carolina,
South Carolina and Georgia) and the rest of the stroke belt (remaining areas of North Carolina,
South Carolina and Georgia and Alabama, Arkansas, Louisiana, Mississippi, and Tennessee)
[28]. The Institutional Review Boards at participating centers approved the study protocol, and
all participants provided written informed consent [28].
Data collection
Information about socio-demographic factors, cardiovascular disease risk factors, cigarette
smoking, physical activity, use of medications, and psychosocial factors including perceived
social support, depressive symptoms, and stress was obtained via computer assisted telephone
interviews [28, 29]. Trained health professionals conducted an in-home visit to obtain systolic
and diastolic blood pressure, weight and height measurements and blood and spot urine sam-
ples [29]. Fasting was requested for 10–12 hours before the in-home visit [28]. Blood and urine
samples were shipped overnight with ice packs to a central laboratory at the University of Ver-
mont and lipid profiles and glucose were obtained from laboratory assays performed on blood
samples [28, 29]. Prescription and nonprescription medication use in the two weeks prior to
the in-home visit was recorded by pill bottle review [28].
Sample selection
For the current analyses, participants were included if they had medication-treated diabetes
(use of anti-diabetes medications), hypertension (use of antihypertensive medication), or dys-
lipidemia (use of lipid lowering medications) and/or prevalent CHD (self-reported history or
electrocardiogram [ECG] evidence of a prior myocardial infarction [MI] or self-reported coro-
nary artery bypass graft, coronary angioplasty, or coronary stenting) and use of CHD-related
medications (nitrates, nitroglycerin, clopidogrel or use of aspirin to reduce risk of MI or
stroke). Participants were excluded because of data anomalies (n = 56), missing data on social
support components (n = 1,985), or medication adherence (n = 517), if they were missing data
on conditions of interest (diabetes, hypertension, dyslipidemia and/or prevalent CHD) or use
of medications for the conditions (n = 5,242) and did not have the conditions of interest or
use medications for these conditions (n = 5,326) (Fig 1). After exclusions, the sample size
was 17,113 participants. Participants excluded because of missing data were more likely to be
younger (64.0 years vs 66.2 years), black (41.7% vs 44.6%), have health insurance (9.1% vs
5.1%), take fewer medications (4.2 vs 7.1), have a higher mean PCS score (47.4 vs 44.7) and
less likely to be female (51.5% vs 53.8%), to have prevalent CHD (18.3% vs 28.9%) and be
obese (36.6% vs 44.3%) compared to those included in the study (Table A in S1 File). Partici-
pants excluded because they did not have conditions of interest or use of medications for the
conditions were more likely to be younger (61.9 years vs 66.2 years), female (64.6% vs 53.8%),
have health insurance (8.1% vs 5.1%), take fewer medications (3.5 vs 7.1), have a higher mean
PCS score (50.4 vs 44.7) and less likely to be black (31.2% vs 44.6%), to have prevalent CHD
(7.0% vs 28.9%) and to be obese (22.0% vs 44.3%) compared to those included in the study
(Table A in S1 File).
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Exposures
Six survey items were used to measure perceived social support. Each social support compo-
nent was considered as a separate exposure variable. Consistent with prior literature [6, 12,
13], social support was further divided into three types: functional support, structural support
and a combination of functional and structural support.
Functional support. One item was used to measure functional support.
1. Care during illness or disability status
Participants were asked, “If you had a serious illness or became disabled, do you have some-
one who would be able to provide care for you on an on going basis?” This item was dichot-
omized as (care during illness or disability vs no one to care during illness or disability).
Structural support. Four items were used to measure structural support.
1. Partnered status
This was based on whether participants were married or in a marriage-like relationship vs
divorced, widowed, separated, never been married. This was dichotomized as partnered vs
not partnered respectively.
2. Number of close friends.
Participants were asked, “How many close friends do you have? That is, people that you feel
Fig 1. Flow chart with exclusion criteria.
https://doi.org/10.1371/journal.pone.0198578.g001
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at ease with, can talk to about private matters, and can call on for help?” This was catego-
rized based on quartiles as 0–2 close friends, 3–4 close friends, 5–6 close friends, and>6
close friends.
3. Number of close relatives
Participants were asked, “How many relatives do you have that you feel close to?” This was
categorized based on quartiles as 0–3 close relatives, 4–5 close relatives, 6–10 close relatives,
and>10 close relatives.
4. Number of other adults in household
Participants were asked, “Not counting yourself, how many adults, age 18 or older currently
live in the same household with you?” Because of limited variation in this item, it was
divided into tertiles as 0 other adults in household, 1 other adult in household, and>1
other adult in household.
Combination of functional and structural support. One item included a combination of
functional and structural support.
1. Frequency of contacts
Participants were asked “How many of these friends or relatives do you see at least once a
month?” This was categorized based on quartiles as seeing 0–3 close friends or relatives at
least monthly, seeing 4–5 close friends or relatives at least monthly, seeing 6–10 close friends
or relatives at least monthly, and seeing>10 close friends or relatives at least monthly.
Outcome
Medication adherence was assessed using a four-item scale (30). Participants responded yes or
no to the following questions: 1) “Do you ever forget to take your medicines?”; 2) “Are you
careless at times about taking your medicine?”; 3) “When you feel better, do you sometimes
stop taking your medicine?” and 4) “Sometimes if you feel worse when you start taking the
medicine, do you stop taking it?” The outcome was categorized as low adherence (at least
one “yes” response) and high adherence (no “yes” responses), consistent with prior literature
[30].
Covariates
Access to medications results from interaction between individuals and the health system, thus
the Andersen and Aday conceptual model was selected to guide the analysis. This model pro-
posed that individual and contextual characteristics determine how and if an individual uses
health services; these characteristics are categorized into predisposing, enabling, and need fac-
tors [31].
Pre-disposing factors. The pre-disposing factors included in the analyses were age (con-
tinuous), race (black vs. white), gender (male vs. female), region of residence (Stroke Buckle
vs. Stroke Belt vs. Non-Belt), annual household income (<$20,000 vs.$20,000) and educa-
tion (high school graduate or less vs. some college or college graduate).
Enabling factors. The enabling factors available for these analyses were insurance status
(yes vs. no), rural status based on Rural Urban Commuting Area [RUCA] Codes [32], (rural
vs. not rural) and percentage of individuals in a zip code living below the federal poverty line
(continuous).
Need factors. The need factors were cumulative number of medications (continuous),
depressive symptoms based on the Center for Epidemiologic Studies–Depression Scale
Social support and medication adherence
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[CES-D] (CES-D score <4 vs.4), physical functioning based on the Short Form 12 Physical
Component Summary [PCS] score [33] (continuous), mental health based on the Short Form
12 Mental Health Component Summary (MCS) score [33] (continuous), Cohen’s perceived
stress scale [34] score (continuous), general health (excellent/very good vs good vs fair/poor),
obesity status based on BMI (kg/m2) estimated from measured height and weight during
the in-home visit (obese vs not obese), physical activity (none vs. 1–3 times per week vs.4
times per week) and Framingham CHD risk score: risk of coronary death or MI over 10
years among those free of CHD at baseline [35, 36] [(<10% vs 10–20% vs >20%) vs prevalent
CHD].
Statistical analysis
Participant characteristics and social support components were compared by medication
adherence status (low versus high adherence) using descriptive statistics. Multivariable-
adjusted Poisson regression models with robust variance estimation were used to calculate
prevalence ratios (PRs) for high medication adherence for each measure of social support as
follows: 1. care during illness or disability vs no one to care during illness or disability; 2. part-
nered vs not partnered; 3. quartiles for number of close friends with 0–2 close friends as the
reference; 4. quartiles for number of close relatives with 0–3 close relatives as the reference; 5.
quartiles for number of close friends or relatives seen at least monthly with seeing 0–3 close
friends or relatives at least monthly as the reference, and 6. tertiles for number of other adults
in household with 0 other adults in household as the reference.
First a crude model was analyzed for each exposure variable. Then, sequential adjustments
were made using three models for each exposure variable based on the Andersen and Aday
conceptual model [31]. The crude model was adjusted for pre-disposing factors (age, race,
gender region of residence, annual household income and education) to create model 1.
Model 2 was created by further adjusting model 1 for enabling factors (insurance status,
rural status and percentage of individuals in a zip code living below the federal poverty line).
Model 2 was further adjusted for need factors (cumulative number of medications, depres-
sive symptoms, MCS score, perceived stress scale score, general health, obesity status,
physical activity, and CHD risk category) to create model 3. Race and gender were tested sep-
arately to determine whether they were effect modifiers of the associations between high
medication adherence and each of the six exposures using cross-product (interaction) terms.
Multivariable-adjusted Poisson regression models with robust variance estimation as above
were used to estimate PRs for high medication adherence separately for each race and gen-
der. Multiple imputation by chained equations with ten datasets was used to account for
missing covariate data [37]. The data was analyzed using SAS, version 9.4, SAS Institute,
Cary, NC.
Results
Among the 17,113 participants, the prevalence of high medication adherence was 68.9%. Par-
ticipants with high medication adherence were more likely to be rural residents (20.5% vs
18.5%), to have higher mean PCS (45.0 vs 43.9) and MCS scores (54.6 vs 53.0), fewer depres-
sive symptoms (10.3% vs 14.3%), and less perceived stress (3.0 vs 3.6) compared to participants
with low medication adherence (Table 1).
In the crude analysis, participants with high medication adherence were more likely to
report having someone to care for them during illness or disability (87.1% vs 84.4%),>6 close
friends (24.4% vs 22.5%),>10 close relatives (16.3% vs 15.3%), to see >10 close friends or rela-
tives at least monthly (20.5% vs 17.6%) and less likely to have >1 other adult in the household
Social support and medication adherence
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(15.4% vs 17.8%) compared to those with low medication adherence (Table 2). Compared to
participants who reported seeing 0–3 close friends or relatives at least monthly, the PRs of high
medication adherence for those who reported seeing 4–5 friends or relatives at least monthly,
6–10 friends or relatives at least monthly and>10 friends or relatives at least monthly were








Age, years, mean ± SD 65.3 ± 9.0 66.7 ± 9.0 <0.0001
Black, n (%) 2,404 (45.2) 5,223 (44.3) 0.29
Women, n (%) 2,948 (55.4) 6,254 (53.0) 0.005
Region, n (%) <0.0001
Stroke beltb 1,915 (36.0) 4,078 (34.6)
Stroke bucklec 1,026 (19.3) 2,646 (22.4)
Non-stroke belt or buckle 2,382 (44.8) 5,066 (43.0)
Annual household income <$20,000, n (%) 1,073 (22.8) 2,294 (22.0) 0.26
Education  High school, n (%) 2,233 (42.0) 4,809 (40.8)
Enabling factors
No health insurance, n (%) 285 (5.4) 585 (5.0) 0.28
Percentage of individuals in a zip code living below the federal poverty line, mean ± SD 17.0 ± 9.5 17.0 ± 9.3 0.92
Rural residence, n (%) 893 (18.5) 2,187 (20.5) 0.004
Need factors
CHDa risk categoriesd, n (%) 0.08
< 10% 2,271 (42.7) 5,142 (43.6)
10–20% 921 (17.3) 2,132 (18.1)
>20% 521 (9.8) 1,175 (10.0)
Prevalent CHDae 1,610 (30.3) 3,341 (28.3)
Physical activityf, n (%) <0.0001
None 2,021 (38.5) 4,212 (36.1)
1–3 times per week 1,918 (36.5) 4,073 (34.9)
4+ times per week 1,316 (25.0) 3,376 (29.0)
Cumulative number of medications ± SD 7.2 ± 4.0 7.0 ± 3.9 0.0009
General Healthf, n (%) <0.0001
Excellent/Very Good 1,831 (34.5) 4,711 (40.0)
Good 2,140 (40.3) 4,491 (38.2)
Fair/Poor 1,343 (25.3) 2,565 (21.8)
Obesity prevalence, n (%) 2,500 (47.4) 5,016 (42.8) <0.0001
Depressive symptoms, CES-D score  4, n (%) 758 (14.3) 1,203 (10.3) <0.0001
Physical Component Summary Score, mean ± SD 43.9 ± 11.0 45.0 ± 10.9 <0.0001
Mental Component Summary Score, mean ± SD 53.0 ± 9.1 54.6 ± 8.2 <0.0001
Perceived Stress Scale Score, mean ± SD 3.6 ± 3.0 3.0 ± 2.9 <0.0001
aAbbreviations: REGARDS, Reasons for Geographic and Racial Differences in Stroke; CHD, coronary heart disease
bDefined as the states of Alabama, Arkansas, Louisiana, Mississippi, Tennessee and the noncoastal regions of North Carolina, South Carolina and Georgia.
cDefined as the coastal regions of North Carolina, South Carolina and Georgia.
dFramingham CHD hard event risk score: risk of coronary death or MI over 10 years (among those free of CHD at baseline).
eSelf-reported history or electrocardiogram (ECG) evidence of a prior myocardial infarction MI or self-reported coronary artery bypass graft, coronary angioplasty, or
coronary stenting.
fThe frequencies and percentages may not add up to the total sample size due to missing data.
https://doi.org/10.1371/journal.pone.0198578.t001
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1.03 (95% CI: 0.98, 1.09), 1.03 (95% CI: 0.99, 1.08) and 1.06 (95% CI: 1.00, 1.11) respectively,
after multivariable adjustment (Table 3).
Black participants were more likely to have>1 other adult in the household compared to
white participants (p<0.001) (Table B in S1 File). Women were less likely to have someone to
care for them during illness or disability (p<0.001) or to be partnered (p<0.001) and were
more likely to have no other adults in the household (p<0.001), compared to men (Table C in
S1 File). The associations between the social support components and medication adherence
were similar between groups defined by race and gender (P-values for interaction >0.10 for all
exposure-effect modifier combinations) (Tables D and E in S1 File).
Discussion
In this study of adults with CHD risk factors (diabetes, hypertension, dyslipidemia and/or
prevalent CHD), the number of close friends or relatives seen at least monthly, a combination
of functional and structural support, was modestly associated with higher medication adher-
ence. The other measures of perceived social support assessed in this study, were not associated
with medication adherence, once factors known to influence health services utilization were
accounted for. However, overall, the prevalence of high medication adherence was notable
(68.9%) given the high-risk status of this population.
Two meta-analyses indicated that functional social support had a stronger association
with treatment adherence (medication adherence and adherence to other self-care activities)
Table 2. Social support components by medication adherence status.
Medication Adherence
Low adherence High adherence p
Functional support
Care during illness or disability, n (%) 4,491 (84.4) 10,274 (87.1) <0.0001
Structural support
Partnered, n (%) 3,239 (60.8) 7,168 (60.8) 0.95
Close Friends (Quartiles) <0.0001
0–2 close friends, n (%) 1,531 (28.8) 3,080 (26.1)
3–4 close friends, n (%) 1,493 (28.1) 3,189 (27.1)
5–6 close friends, n (%) 1,101 (20.7) 2,643 (22.4)
>6 close friends, n (%) 1,198 (22.5) 2,878 (24.4)
Close Relatives (Quartiles) 0.0002
0–3 close relatives, n (%) 2,012 (37.8) 4,057 (34.4)
4–5 close relatives, n (%) 1,141 (21.4) 2,566 (21.8)
6–10 close relatives, n (%) 1,357 (25.5) 3,243 (27.5)
>10 close relatives, n (%) 813 (15.3) 1,924 (16.3)
Other adults in household (Tertiles) 0.0004
0 other adults in household, n (%) 1,417 (26.6) 3,246 (27.5)
1 other adult in household, n (%) 2,957 (55.6) 6,725 (57.0)
>1 other adult in household, n (%) 949 (17.8) 1,819 (15.4)
Functional and structural support
Frequency of Contacts (Quartiles) <0.0001
Seeing 0–3 close friends or relativesat least monthly, n (%) 1,957 (36.8) 3,812 (32.3)
Seeing 4–5 close friends or relativesat least monthly, n (%) 1,025 (19.3) 2,320 (19.7)
Seeing 6–10 close friends or relativesat least monthly, n (%) 1,402 (26.3) 3,239 (27.5)
Seeing >10 close friends or relativesat least monthly, n (%) 939 (17.6) 2,419 (20.5)
https://doi.org/10.1371/journal.pone.0198578.t002
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compared to structural social support in adults and children with a range of conditions includ-
ing hypertension [6, 14]. The current study added new data which suggests that the combina-
tion of functional and structural social support via interactions with close friends or relatives
may have a greater impact on medication adherence compared to other measures of functional
or structural social support. Collectively, these results suggest that the quality of relationships
may have a greater impact on medication adherence compared to the number of individuals
in one’s social network [6]. The mechanisms behind this are unclear; it has been proposed that
functional support received from relatives or friends as well as assistance provided for self-care
activities facilitates medication adherence [9]. This functional support further aids individuals
to cope and to be motivated and optimistic about different aspects of self-management of their
chronic conditions [6, 9, 38]. As a result of supportive interactions that lead to better coping,
suggested interventions to improve medication adherence include encouraging social network
members to assist non-adherent members with prescription refills and pill reminders [11].
Table 3. Adjusted models with prevalence ratios and 95% confidence intervals of high medication adherence by social support components.
Crude Model Model 1a Model 2b Model 3c
PR 95% CI PR 95% CI PR 95% CI PR 95% CI
Functional support
Care during illness or disability vsNo one to care during illness or disability 1.08 (1.02, 1.14) 1.08 (1.02, 1.14) 1.08 (1.02, 1.14) 1.05 (0.99, 1.11)
Structural support
Partnered vs not partnered 1.00 (0.96, 1.04) 1.00 (0.96, 1.04) 1.00 (0.96, 1.04) 0.99 (0.95, 1.04)
Close Friends (Quartiles)
0–2 close friends Ref Ref Ref Ref
3–4 close friends 1.02 (0.97, 1.07) 1.02 (0.97, 1.07) 1.01 (0.97, 1.07) 1.01 (0.96, 1.06)
5–6 close friends 1.06 (1.00, 1.11) 1.05 (1.00, 1.11) 1.05 (1.00, 1.11) 1.03 (0.98, 1.09)
>6 close friends 1.06 (1.00, 1.11) 1.05 (0.99, 1.10) 1.05 (0.99, 1.10) 1.02 (0.97, 1.08)
Close Relatives (Quartiles)
0–3 close relatives Ref Ref Ref Ref
4–5 close relatives 1.04 (0.99, 1.09) 1.04 (0.99, 1.09) 1.04 (0.99, 1.09) 1.02 (0.97, 1.07)
6–10 close relatives 1.06 (1.01, 1.10) 1.05 (1.00, 1.10) 1.05 (1.00, 1.10) 1.03 (0.98, 1.08)
>10 close relatives 1.05 (1.00, 1.11) 1.04 (0.99, 1.10) 1.04 (0.98, 1.10) 1.02 (0.96, 1.07)
Other adults in household (Tertiles)
0 other adults in household Ref Ref Ref Ref
1 other adult in household 1.00 (0.96, 1.04) 1.00 (0.96, 1.05) 1.00 (0.96, 1.05) 1.00 (0.96, 1.05)
>1 other adult in household 0.94 (0.89, 1.00) 0.96 (0.91, 1.02) 0.97 (0.91, 1.03) 0.97 (0.92, 1.03)
Functional and structural support
Frequency of Contacts
Seeing 0–3 close friends or relativesat least monthly Ref Ref Ref Ref
Seeing 4–5 close friends or relativesat least monthly 1.05 (1.00, 1.10) 1.05 (1.00, 1.10) 1.05 (1.00, 1.10) 1.03 (0.98, 1.09)
Seeing 6–10 close friends or relativesat least monthly 1.06 (1.01, 1.11) 1.06 (1.01, 1.11) 1.06 (1.01, 1.11) 1.03 (0.99, 1.08)
Seeing >10 close friends or relativesat least monthly 1.09 (1.04, 1.15) 1.09 (1.03, 1.14) 1.09 (1.03, 1.14) 1.06 (1.00, 1.11)
aModel 1(Pre-disposing factors): age (continuous), race (categorical), gender (categorical), region of residence (categorical), annual household income (categorical) and
education (categorical).
bModel 2 (Enabling factors): model 1 covariates, insurance status (categorical), rural status (categorical), percentage of individuals in a zip code living below the federal
poverty line (continuous).
cModel 3 (Need factors): model 2 covariates, cumulative number of medications (continuous), depressive symptoms, (CES-D) score (categorical), physical component
summary score (continuous), mental component summary score (continuous), perceived stress scale score (continuous), general health (categorical), obesity status
(categorical), physical activity (categorical), coronary heart disease risk category (categorical).
https://doi.org/10.1371/journal.pone.0198578.t003
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The current study may have had limited power to detect clinically important variations by
race and gender in the associations between social support and medication adherence. Prior
studies have found differences in the associations between social support and chronic disease
self-management activities by race and gender. One study found that among women, diabetes-
specific social support was associated with an increased prevalence of medication adherence
among people with diabetes; however, among men, social support was not associated with
medication adherence [39]. In another study, Rees and colleagues found that the association
between social support and diabetes self-management activities differed by race [40]. However,
medication adherence was not assessed in this study.
The strengths of the current study include the availability of data on a four-item medication
adherence scale, social support components, health-related and socio-economic variables on a
large population of black and white men and women from the 48 contiguous US states.
The current study has several potential limitations. This was a cross-sectional study;
therefore, it was not possible to determine the temporality sequence between social
support components and medication adherence. The cross-sectional nature of the study
further limits our ability to make causal inferences regarding whether social support
directly influences medication adherence. Since social support and medication adherence
were both self-reported, it is possible that misclassification may have resulted. However, the
four-item medication adherence scale used in the current analysis has been widely used,
including in prior studies using the REGARDS data to evaluate anti-hypertensive medica-
tion [41] and statin [42] adherence. We relied on the participants’ perceptions of social
support; we did not have information about whether unexpected support may have been
provided in times of need. Further, the reporting of both social support and medication
adherence may be affected by social desirability bias. Additionally, only one measure of
functional support was available; therefore, this limits the ability to make further conclu-
sions regarding the association between functional support and medication adherence.
Some covariates relied also on self-report, which could have increased the potential for mis-
classification. Although a variety of confounders were accounted for, there was potential for
residual confounding.
Conclusions
The results of the current study indicate that among people with CHD risk factors, frequent
contact with close friends or relatives (which comprises a combination of functional and
structural social support) had a small association with medication adherence. Enhancing
combined functional and structural social support for people with CHD risk factors such as
diabetes, hypertension, dyslipidemia and prevalent CHD may help improve their medication
adherence.
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